Viking Therapeutics Inc (VKTX)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Viking Therapeutics Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 7 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 32.60 $ — 50% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
1/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% –
- Exp. sales growth 3Y > 5% –
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% –
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% -56.3%
- ROCE > 15% -61.5%
- Expected return > 10% –
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
2 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years no data
- More than 10% revenue growth is expected for the coming year 0.0% failed
- Share count grows by less than 3% a year 13.6% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") no data
- Gross margin at 40% or higher and without meaningful erosion no data
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 706 m net cash passed
- Operating cash flow covers the profits of the last three years 116 m failed
- Return on capital at 15% or higher, or up versus two years ago -61.6% failed
- Insiders hold at least 10% or are net buyers 2.8% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 185.3% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 19
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -4.61 | -5.35 – -3.81 | 0 | -44.5% | 15 |
| 12/31/2027 | -4.39 | -6.41 – -2.22 | 0 | 4.7% | 17 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.32 | – | 0 | -100.00 | – | -31 | -31 |
| 2025: Q1 | -0.41 | – | 0 | – | – | -52 | -52 |
| 2025: Q2 | -0.58 | – | 0 | – | – | -47 | -47 |
| 2025: Q3 | -0.81 | – | 0 | – | – | -94 | -94 |
| 2025: Q4 | -1.38 | – | 0 | – | – | -85 | -85 |
| 2026: Q1 | -1.37 | – | 0 | – | – | -114 | -114 |
| 2026: Q2 | -1.10 | -89.70 | 0 | – | – | -125 | -125 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 0 | -14 | -15 | -0.91 | -11 | 8 | 15 |
| 2017 | 0 | -19 | -21 | -0.79 | -15 | 13 | 22 |
| 2018 | 0 | -26 | -22 | -0.38 | -19 | 298 | 302 |
| 2019 | 0 | -33 | -26 | -0.36 | -25 | 277 | 284 |
| 2020 | 0 | -43 | -40 | -0.54 | -22 | 244 | 257 |
| 2021 | 0 | -56 | -55 | -0.71 | -48 | 202 | 211 |
| 2022 | 0 | -70 | -69 | -0.90 | -48 | 145 | 169 |
| 2023 | 0 | -101 | -86 | -0.91 | -73 | 348 | 368 |
| 2024 | 0 | -151 | -110 | -1.01 | -88 | 880 | 908 |
| 2025 | 0 | -393 | -360 | -3.19 | -279 | 639 | 716 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Viking Therapeutics, Inc., ein biopharmazeutisches Unternehmen im klinischen Stadium, konzentriert sich auf die Entwicklung neuartiger Therapien für Stoffwechsel- und endokrine Störungen.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 59 |
| Headquarters | San Diego, CA |
| Address | 9920 Pacific Heights Boulevard, 92121 San Diego, United States |
| Phone | 858 704 4660 |
| Website | vikingtherapeutics.com |
| IPO Date | 29. Apr 2015 |
| ISIN | US92686J1060 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Brian Lian Ph.D. | President, CEO & Director | 1966 |
| Marianne Mancini | Chief Operating Officer | 1965 |
| Michael Morneau | Vice President of Finance & Administration | 1965 |
| Kenneth J. Herman M.B.A. | Senior Vice President of Commercial, Marketing & Sales | – |
| Geoffrey E. Barker Ph.D. | Chief Development Officer | – |
| Nils U. Olsson Ph.D. | Senior Vice President of Technical Operations | – |
| Hubert C. Chen M.D., M.P.H. | Chief Medical Officer | 1969 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 29. Jul 2026 | Lian Brian | President & CEO | Sell | 148,517 | 33.32 | 4,947,888 |
| 29. Jul 2026 | Zante Greg | Chief Financial Officer | Sell | 21,217 | 33.47 | 710,141 |
| 29. Jul 2026 | Mancini Marianna | Chief Operating Officer | Sell | 18,217 | 33.47 | 609,636 |
| 28. Jul 2026 | Lian Brian | President & CEO | Other | 221,667 | 0.00 | – |
| 28. Jul 2026 | Zante Greg | Chief Financial Officer | Other | 31,667 | 0.00 | – |
| 28. Jul 2026 | Mancini Marianna | Chief Operating Officer | Other | 31,667 | 0.00 | – |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.